Arlevert 20 mg / 40 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

arlevert 20 mg / 40 mg tabletti

hennig arzneimittel gmbh&co kg - cinnarizine, dimenhydrinate - tabletti - 20 mg / 40 mg - sinnaritsiini

CINACALCET MEDICE 90 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

cinacalcet medice 90 mg tabletti, kalvopäällysteinen

medice arzneimittel pütter gmbh & co. kg - cinacalcetum hydrochloridum - tabletti, kalvopäällysteinen - 90 mg - sinakalseetti

Lidobel vet. 16 mg/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

lidobel vet. 16 mg/ml injektioneste, liuos

bela-pharm gmbh & co. kg - lidocaine hydrochloride monohydrate - injektioneste, liuos - 16 mg/ml - lidokaiini

Ketabel vet. 100 mg/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

ketabel vet. 100 mg/ml injektioneste, liuos

bela-pharm gmbh & co. kg - ketamine hydrochloride - injektioneste, liuos - 100 mg/ml - ketamiini

Axhidrox 2,2 mg/pumpun käyttökerta emulsiovoide Suomi - suomi - Fimea (Suomen lääkevirasto)

axhidrox 2,2 mg/pumpun käyttökerta emulsiovoide

dr. august wolff gmbh & co. kg arzneimittel - glycopyrronium bromide - emulsiovoide - 2,2 mg/pumpun käyttökerta - glykopyrronium

ESBERITOX  tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

esberitox tabletti

schaper & brummer gmbh & co.kg - echinacea purpurea root,echinacea kalpea root,tuija occididentalis kasvi,baptisia tinctoria root - tabletti - muut vilustumislÄÄkkeet

Belfer vet. 100 mg/ml injektioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

belfer vet. 100 mg/ml injektioneste, liuos

bela-pharm gmbh & co. kg - iron dextran complex - injektioneste, liuos - 100 mg/ml - rauta

Alacare 8 mg lääkelaastari Suomi - suomi - Fimea (Suomen lääkevirasto)

alacare 8 mg lääkelaastari

photonamic gmbh & co. kg - 5-aminolevuliinihappo-hydrokloridi - lääkelaastari - 8 mg - aminolevuliinihappo

Rinvoq Euroopan unioni - suomi - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - niveltulehdus, nivelreuma - immunosuppressantit - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Skyrizi Euroopan unioni - suomi - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressantit - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.